Related Experiment Video
Updated: Jun 13, 2026
07:25
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Hepatitis B surface antigen seroclearance during chronic HBV infection.
1Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan.
Antiviral Therapy
|April 14, 2010
Summary
Hepatitis B surface antigen (HBsAg) seroclearance is achievable in 1-2% of chronic hepatitis B virus (HBV) infections annually. Excellent long-term outcomes are expected post-HBsAg seroclearance, especially without prior cirrhosis.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Chronic hepatitis B virus (HBV) infection affects millions globally.
- Hepatitis B surface antigen (HBsAg) seroclearance signifies a major milestone in HBV infection.
- Spontaneous and treatment-induced HBsAg seroclearance are key goals in HBV management.
Purpose of the Study:
- To review spontaneous HBsAg seroclearance in chronic HBV infection.
- To identify viral and host factors predicting HBsAg seroclearance.
- To discuss outcomes and profiles following HBsAg seroclearance, including antiviral therapy effects.
Main Methods:
- Systematic review of diverse studies on spontaneous HBsAg seroclearance.
- Analysis of predictive factors for seroclearance (viral and host).
- Review of studies on antiviral therapy, particularly interferon, and its impact on seroclearance.
Main Results:
- HBsAg seroclearance occurs annually in 1-2% of chronic HBV patients.
- Excellent long-term outcomes are observed post-seroclearance in the absence of cirrhosis or superinfection.
- Various viral and host factors influence the likelihood of HBsAg seroclearance.
Conclusions:
- HBsAg seroclearance is an important therapeutic endpoint in chronic HBV infection.
- Understanding predictive factors can optimize patient selection for therapies aimed at seroclearance.
- Further research into achieving and maintaining HBsAg seroclearance is crucial for improving patient outcomes.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:09Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance
Hepatic clearance refers to the volume of blood cleared of a drug by the liver per unit of time. It plays a crucial role in drug metabolism and elimination. While hepatic clearance is commonly estimated by subtracting renal clearance from total body clearance, other pathways, such as pulmonary or biliary clearance, may also contribute. However, these pathways are generally less significant than hepatic and renal clearance.
Most drugs undergo restrictive clearance, which is proportional to the...
Most drugs undergo restrictive clearance, which is proportional to the...
01:09Hepatic Drug Clearance: Effect of Protein Binding
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
01:23Genital Herpes
Genital herpes is a sexually transmitted infection primarily caused by herpes simplex virus type 2 (HSV-2), though herpes simplex virus type 1 (HSV-1) is increasingly implicated in genital infections, particularly among younger populations. Transmission occurs mainly through sexual contact, with asymptomatic viral shedding serving as a major route of spread. This characteristic makes HSV-2 difficult to control at a population level, as individuals may unknowingly transmit the virus even in the...